Table 1 Antibiotic resistance rates and frequency of resistance genes among NDM positive and negative isolates
NDM positive (n = 21) | NDM negative (n = 101) | NDM positive vs. NDM negative P value | |
|---|---|---|---|
Resistance rates n (%) | |||
Imipenem | 21 (100) | 24 (23.8%) | 0.001 |
Meropenem | 21 (100) | 20 (19.8%) | 0.001 |
Ertapenem | 21 (100) | 30 (29.7%) | 0.001 |
Cefepime | 20 (95.2) | 39 (38.6%) | 0.001 |
Ceftazidime | 21 (100) | 52 (51.5%) | 0.001 |
Cefotaxime | 21 (100) | 66 (65.3%) | 0.001 |
Aztreonam | 21 (100) | 51 (50.5%) | 0.001 |
Ampicillin/sulbactam | 21 (100) | 54 (53.5%) | 0.001 |
Piperacillin/tazobactam | 21 (100) | 36 (35.3%) | 0.001 |
Amoxicillin/clavulanate | 21 (100) | 53 (52.5%) | 0.001 |
Ciprofloxacin | 20 (95.2) | 48 (47.5%) | 0.001 |
Levofloxacin | 20 (95.2) | 37 (36.6%) | 0.001 |
Gentamicin | 20 (95.2) | 28 (27.7%) | 0.001 |
Tobramycin | 20 (95.2) | 33 (32.7%) | 0.001 |
Amikacin | 8 (38.1) | 10 (9.9%) | 0.003 |
Trimethoprim/sulphamethoxazole | 18 (85.7) | 46 (45.5%) | 0.001 |
MDR | 21 (100) | 54 (53.5) | 0.001 |
Presence of resistance and capsular markers n (%) | |||
armA | 10 (47.6) | 16 (15.8%) | 0.003 |
rmtC | 3 (14.3) | 3 (3%) | 0.06* |
aac6Ib | 14 (66.7) | 35 (34.7%) | 0.01 |
aac3IIa | 19 (90.5) | 28 (27.5%) | 0.001 |
qnrB | 1 (4.8) | 22 (21.8%) | 0.1 |
qnrS | 18 (85.7) | 17 (16.8%) | 0.001 |
aac6Ib-cr | 19 (90.5) | 47 (47%) | 0.001 |
blaOXA-48 | 14 (66.7) | 21 (20.8%) | 0.001 |
blaIMP- | 0 | 3 (3%) | 1 |
CTX-M-G1 | 21 (100) | 53 (52.5%) | 0.001 |
CTX-M-G2 | 0 | 3 (3%) | 0.5 |
CTX-M-G8 | 0 | 2 (2.0%) | 0.6 |
CTX-M-G9 | 0 | 2 (2.0%) | 0.6 |
CTX-M-G25 | 0 | 7 (7%) | 0.2 |
blaTEM- | 12 (57.1) | 29 (28.7%) | 0.02 |
blaSHV- | 19 (90.5) | 67 (66.3%) | 0.03 |
blaOXA-1 | 15 (71.4) | 25 (24.8) | 0.001 |
K1 | 0 | 1 (1%) | 1 |
K2 | 0 | 15 (14.8) | 0.07 |